Runze Yang1,2,3, Susobhan Sarkar2,3, Daniel J Korchinski1,2,3, Ying Wu1,2,3, V Wee Yong2,3,4, Jeff F Dunn1,2,3. 1. Department of Radiology, University of Calgary, Calgary, Alberta, Canada. 2. Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada. 3. Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada. 4. Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Abstract
Background: Glioblastoma (GBM) is an aggressive brain cancer with a poor prognosis. The use of immune therapies to treat GBM has become a promising avenue of research. It was shown that amphotericin B (Amp B) can stimulate the innate immune system and suppress the growth of brain tumor initiating cells (BTICs). However, it is not feasible to use histopathology to determine immune activation in patients. We developed an MRI technique that can rapidly detect a therapeutic response in animals treated with drugs that stimulate innate immunity. Ultra-small iron oxide nanoparticles (USPIOs) are MRI contrast agents that have been widely used for cell tracking. We hypothesized that the increased monocyte infiltration into brain tumors due to Amp B can be detected using USPIO-MRI, providing an indicator of early drug response. Methods: We implanted human BTICs into severe combined immunodeficient mice and allowed the tumor to establish before treating the animals with either Amp B or vehicle and then imaged them using MRI with USPIO (ferumoxytol) contrast. Results: After 7 days of treatment, there was a significantly decreased T2* in the tumor of Amp B but not vehicle animals, suggesting that USPIO is carried into the tumor by monocytes. We validated our MRI results with histopathology and confirmed that Amp B-treated animals had significantly higher levels of macrophage/microglia that were colocalized with iron staining in their brain tumor compared with vehicle mice. Conclusion: USPIO-MRI is a promising method of rapidly assessing the efficacy of anticancer drugs that stimulate innate immunity.
Background: Glioblastoma (GBM) is an aggressive brain cancer with a poor prognosis. The use of immune therapies to treat GBM has become a promising avenue of research. It was shown that amphotericin B (Amp B) can stimulate the innate immune system and suppress the growth of brain tumor initiating cells (BTICs). However, it is not feasible to use histopathology to determine immune activation in patients. We developed an MRI technique that can rapidly detect a therapeutic response in animals treated with drugs that stimulate innate immunity. Ultra-small iron oxide nanoparticles (USPIOs) are MRI contrast agents that have been widely used for cell tracking. We hypothesized that the increased monocyte infiltration into brain tumors due to Amp B can be detected using USPIO-MRI, providing an indicator of early drug response. Methods: We implanted humanBTICs into severe combined immunodeficientmice and allowed the tumor to establish before treating the animals with either Amp B or vehicle and then imaged them using MRI with USPIO (ferumoxytol) contrast. Results: After 7 days of treatment, there was a significantly decreased T2* in the tumor of Amp B but not vehicle animals, suggesting that USPIO is carried into the tumor by monocytes. We validated our MRI results with histopathology and confirmed that Amp B-treated animals had significantly higher levels of macrophage/microglia that were colocalized with iron staining in their brain tumor compared with vehicle mice. Conclusion: USPIO-MRI is a promising method of rapidly assessing the efficacy of anticancer drugs that stimulate innate immunity.
Authors: Michael P Gustafson; Yi Lin; Kent C New; Peggy A Bulur; Brian Patrick O'Neill; Dennis A Gastineau; Allan B Dietz Journal: Neuro Oncol Date: 2010-02-23 Impact factor: 12.300
Authors: Machteld M Vellinga; Hugo Vrenken; Hanneke E Hulst; Chris H Polman; Bernard M J Uitdehaag; Petra J W Pouwels; Frederik Barkhof; Jeroen J G Geurts Journal: J Magn Reson Imaging Date: 2009-04 Impact factor: 4.813
Authors: Susobhan Sarkar; Axinia Döring; Franz J Zemp; Claudia Silva; Xueqing Lun; Xiuling Wang; John Kelly; Walter Hader; Mark Hamilton; Philippe Mercier; Jeff F Dunn; Dave Kinniburgh; Nico van Rooijen; Stephen Robbins; Peter Forsyth; Gregory Cairncross; Samuel Weiss; V Wee Yong Journal: Nat Neurosci Date: 2013-12-08 Impact factor: 24.884
Authors: Sook Namkung; Christoph J Zech; Thomas Helmberger; Maximilian F Reiser; Stefan O Schoenberg Journal: J Magn Reson Imaging Date: 2007-04 Impact factor: 4.813
Authors: Seymur Gahramanov; Leslie L Muldoon; Csanad G Varallyay; Xin Li; Dale F Kraemer; Rongwei Fu; Bronwyn E Hamilton; William D Rooney; Edward A Neuwelt Journal: Radiology Date: 2012-11-30 Impact factor: 11.105
Authors: Bruce S Spinowitz; Annamaria T Kausz; Jovanna Baptista; Sylvia D Noble; Renuka Sothinathan; Marializa V Bernardo; Louis Brenner; Brian J G Pereira Journal: J Am Soc Nephrol Date: 2008-06-04 Impact factor: 10.121
Authors: Stephanie M Pyonteck; Leila Akkari; Alberto J Schuhmacher; Robert L Bowman; Lisa Sevenich; Daniela F Quail; Oakley C Olson; Marsha L Quick; Jason T Huse; Virginia Teijeiro; Manu Setty; Christina S Leslie; Yoko Oei; Alicia Pedraza; Jianan Zhang; Cameron W Brennan; James C Sutton; Eric C Holland; Dylan Daniel; Johanna A Joyce Journal: Nat Med Date: 2013-09-22 Impact factor: 53.440
Authors: Amr Alaarg; Carlos Pérez-Medina; Josbert M Metselaar; Matthias Nahrendorf; Zahi A Fayad; Gert Storm; Willem J M Mulder Journal: Adv Drug Deliv Rev Date: 2017-05-12 Impact factor: 15.470
Authors: Runze Yang; A Max Hamilton; Hongfu Sun; Khalil S Rawji; Susobhan Sarkar; Reza Mirzaei; G Bruce Pike; V Wee Yong; Jeff F Dunn Journal: Cancer Immunol Immunother Date: 2022-10-04 Impact factor: 6.630
Authors: Lei Deng; Jason H Stafford; Shie-Chau Liu; Sophia B Chernikova; Milton Merchant; Lawrence Recht; J Martin Brown Journal: Neoplasia Date: 2016-12-07 Impact factor: 5.715